Craig Sable, M.D., receives the American Heart Association's Cardiovascular Disease in the Young (CVDY) 2018 Meritorious Achievement Award
Washington cardiologist honored at Scientific Sessions 2018 for accelerating global health research strategies
WASHINGTON, Nov. 15, 2018 /PRNewswire-PRWeb/ -- Craig Sable, M.D., associate chief of the division of cardiology and director of echocardiography at Children's National Health System, earned a lifetime achievement award, formally known as the 2018 Cardiovascular Disease in the Young (CVDY) Meritorious Achievement Award, on Nov. 10 at the American Heart Association's Scientific Sessions 2018.
The CVDY Council bestows the prestigious award to individuals making a significant impact in the field of cardiovascular disease in the young. The CVDY Council supports the mission to improve the health of children and adults with congenital heart disease and acquired heart disease during childhood through research, education, prevention and advocacy.
Dr. Sable is recognized for his entire body of research, education and advocacy focused on congenital and acquired heart disease, but especially for his rheumatic heart disease (RHD) research in Uganda.
Over the past 15 years, Dr. Sable has brought more than 100 doctors and medical staff to Kampala, the capital and largest city in Uganda, partnering with more than 100 local doctors and clinicians to develop a template for a sustainable infrastructure to diagnose, treat and prevent both RHD and congenital heart disease.
RHD is a result of damage to the heart valves after acute rheumatic fever (ARF). The process starts with a sore throat from streptococcal infection, which many children in the United States treat with antibiotics.
"For patients who develop strep throat, their body's reaction to the strep throat, in addition to resolving its primary symptoms, can result in attacking the heart," says Dr. Sable. "The initial damage is called acute rheumatic fever. In many cases this disease is self-limited, but if undetected, over years, it can lead to long-term heart valve damage called rheumatic heart disease. Unfortunately, once severe RHD develops the only treatment is open-heart surgery."
In 2017, Sable and the researchers published a study in the New England Journal of Medicine about the global burden of RHD, which is often referred to as a disease of poverty.
RHD is observed more frequently in low- and middle-income countries as well as in marginalized communities in high-income countries. RHD has declined on a global scale, but it remains the most significant cause of morbidity and mortality from heart disease in children and young adults throughout the world.
In 2017 there were 39.4 million causes of RHD, which resulted in 285,000 deaths and 9.4 million disability-adjusted life-years.
In 2018 the World Health Organization issued a referendum recognizing rheumatic heart disease as an important disease that member states and ministries of health need to prioritize in their public health efforts.
The common denominator that drives Dr. Sable and the global researchers, many of whom have received grants from the American Heart Association to study RHD, is the impact that creating a scalable solution, such as widespread adoption of vaccines, can have on entire communities.
"The cost of an open-heart surgery in Uganda is $5,000 to $10,000, while treatment for a child with penicillin for one year costs less than $1," says Dr. Sable. "Investment in prevention strategies holds the best promise on a large scale to eradicate rheumatic heart disease."
Sable and the team have screened more than 100,000 children and are conducting the first randomized controlled RHD trial, enrolling nearly 1,000 children, to examine the effectiveness of using penicillin to prevent progression of latent or subclinical heart disease, the earliest form of RHD.
During the Thanksgiving holiday weekend, Dr. Sable and a team of surgeons will fly back to Uganda to operate on children affected by RHD, while also advancing their research efforts to produce a scalable solution, exported on a global scale, to prevent RHD in its earliest stages.
Dr. Sable and colleagues from around the world partner on several grant-funded research projects. Over the next few years, the team hopes to answer several important questions, including: Does penicillin prevent the earliest form of RHD and can we develop a vaccine to prevent RHD?
To view the team's previously-published research, visit Sable's PubMed profile.
To learn about global health initiatives led by researchers at Children's National, visit http://www.GHICN.org.
Media contact: Jessica Frost | 301-828-7521| 202-476-4500
SOURCE Children's National Health System
Share this article